GLP-1 Medications: Dose Ladders, Titration Schedules and Pen vs Vial Math

The class is defined by its receptor target. A GLP-1 receptor agonist mimics glucagon-like peptide-1, a gut hormone released after eating that increases glucose-dependent insulin secretion, slows gastric emptying and reduces appetite through hypothalamic signalling. Three generations now sit under the same clinical umbrella.

• Single GLP-1 receptor agonists. Semaglutide, liraglutide, dulaglutide and exenatide. These act on one receptor and differ mainly in half-life, which is what sets daily versus weekly dosing.
• Dual agonists. Tirzepatide activates both the GIP and the GLP-1 receptor. Strictly it is not a pure GLP-1 drug, but it is prescribed, titrated and discussed alongside the class, so it belongs in any practical dosing comparison.
• Investigational multi-agonists. Retatrutide adds glucagon-receptor activity to the same backbone. It has no marketing approval and no label schedule, so any dosing you see quoted for it comes from trial protocols rather than from an approved product.

Same molecule, two different labels

One detail trips up almost everyone comparing doses. A single molecule can carry two brand names with two different dose ceilings, because it was approved separately for type 2 diabetes and for chronic weight management. Semaglutide tops out at 2 mg once weekly on its diabetes label and 2.4 mg once weekly on its weight-management label. Tirzepatide runs to 15 mg once weekly on both. When someone says they take 1 mg, the number only means something once you know which product and which indication it belongs to.

Semaglutide is also the one member of the class with an oral formulation. The tablet uses an absorption enhancer to cross the gut wall, which is why oral doses are quoted in milligrams that look nothing like the injectable ones. Comparing an oral 14 mg tablet to a 1 mg injection is meaningless: the bioavailability is completely different.

The starting dose of a GLP-1 medication is a tolerance dose. The labelling for once-weekly semaglutide is explicit that the 0.25 mg starting dose is for treatment initiation and is not intended to be effective for glycaemic control [1]. The same logic applies across the class.

The reason is mechanical. The receptor activity that produces the benefit also slows gastric emptying and stimulates the area postrema, which is what generates nausea, early fullness, reflux and constipation. Those effects are dose related and they fade with continued exposure at a given dose. Escalating in steps lets the tolerance build before the next increment lands. Jumping straight to a maintenance dose usually produces the same end-state efficacy with a far higher chance of stopping in week two because of vomiting.

What the four-week step actually buys

• Receptor adaptation. Gastric emptying slows sharply at first and partially normalises with repeated dosing, so the same dose feels different in week four than in week one.
• Steady state. Weekly products with a roughly seven-day half-life need about four to five weeks to reach steady plasma concentrations. Escalating earlier means stacking a new dose on top of a level that has not settled.
• A clean read on side effects. If nausea appears three days after a step up, the cause is unambiguous. If you step up every week, it is not.

This is also why a gap in dosing matters. Tolerance is exposure-dependent, so a long break commonly means re-titrating from a lower rung rather than resuming where you stopped.

These are the escalation schedules published in the approved labelling for each product. They are the default starting point, not a prescription: clinicians routinely hold a dose longer, split a step, or stop the climb early when the response is already adequate.

Reading the ladder in calendar terms

For a once-weekly product with four-week steps, the arithmetic is worth doing before you start. Semaglutide takes 16 weeks of climbing to reach 2.4 mg. Tirzepatide reaches 15 mg after roughly 20 weeks if every step is taken at the minimum interval. Daily liraglutide compresses the same idea into five weeks because the steps are weekly.

What the ladders share is a fixed interval and a fixed increment. What they do not share is a rule that you must reach the top. In the pivotal weight-management trials of once-weekly semaglutide, participants who reached 2.4 mg lost roughly 15 percent of body weight on average over 68 weeks, and tirzepatide produced roughly 15 to 21 percent over 72 weeks across its 5 mg, 10 mg and 15 mg arms [3][4]. The dose response is real, but it flattens, and a tolerated 10 mg beats an abandoned 15 mg.

The dose written on a prescription is a mass in milligrams. How you get that mass into the tissue depends entirely on the format.

Prefilled pens

A pen removes the maths. Single-dose pens deliver one fixed amount per device, and multi-dose pens dial to preset positions. Your job is to confirm the device matches the dose you were prescribed, attach a new needle, prime according to the instructions for use, and hold the button for the stated count so the full volume leaves the cartridge. The most common pen error is not a dose error at all: it is withdrawing the needle early and losing part of the dose to a droplet at the skin.

Vials

A vial reintroduces arithmetic. Some vials arrive as a ready-made solution at a stated concentration; lyophilised vials must be reconstituted first, which means the concentration is created by whoever adds the diluent. Two steps then convert milligrams into what you can actually read on a U-100 insulin syringe:

• Concentration (mg/mL) = vial contents in mg divided by diluent volume in mL.
• Units = (dose in mg divided by concentration in mg/mL) multiplied by 100, because 1 unit on a U-100 syringe is 0.01 mL.

Worked examples

• A 10 mg tirzepatide vial reconstituted with 1 mL gives 10 mg/mL. A 2.5 mg starting dose is 0.25 mL, which is 25 units. A 5 mg dose is 50 units.
• The same 10 mg vial reconstituted with 2 mL gives 5 mg/mL. Now the identical 2.5 mg dose is 50 units and 5 mg fills the whole 100 unit barrel.
• A 5 mg semaglutide vial reconstituted with 2 mL gives 2.5 mg/mL. A 0.25 mg starting dose is 10 units, 1 mg is 40 units and 2.4 mg is 96 units.

Notice that the dose never changed in those examples. Only the dilution did. This is the single most important idea in vial dosing and the source of most tenfold errors: units are a volume, not a dose. Anyone quoting "20 units" without stating the concentration has told you nothing. Our syringe measurement guide covers reading the barrel correctly, the reconstitution guide covers the dilution step, and the dose calculator does the conversion for a given vial size and dose.

Where you settle on the ladder is a clinical decision built from several inputs, none of which is the number someone else takes.

Indication and label ceiling

The approved maximum differs by product and by indication, as the table above shows. A prescriber working within a diabetes label has a different ceiling from one working within a weight-management label, even for the same molecule.

Tolerability

Nausea, vomiting, diarrhoea, constipation and reflux are the dose-limiting effects for most people. Persistent symptoms at a given rung are the usual reason a clinician holds the dose or steps back down rather than continuing to climb.

Response

If glycaemic targets or weight goals are being met at an intermediate dose, there is no automatic reason to keep escalating. Several labels explicitly allow maintenance at a lower dose when the higher one is not tolerated.

Other medicines

Adding a GLP-1 medication to insulin or a sulfonylurea raises hypoglycaemia risk, and prescribers commonly reduce the dose of those agents at the same time. Because gastric emptying slows, the absorption of some oral medicines taken at the same time can shift, which matters most for narrow-therapeutic-index drugs.

History that rules the class out

These medicines carry a boxed warning about thyroid C-cell tumours based on rodent studies, and they are contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN 2 [1][2]. A history of pancreatitis, severe gastroparesis, active gallbladder disease, pregnancy or planned pregnancy all change the calculation. This is exactly the material that belongs in a consultation, not in a checkout flow.

Beyond weight and glucose, the cardiovascular evidence has also moved. In a large outcomes trial in people with established cardiovascular disease and overweight or obesity but without diabetes, once-weekly semaglutide 2.4 mg reduced major adverse cardiovascular events compared with placebo [5]. That result is one more reason dose decisions belong with a clinician who can weigh the whole picture.

Weekly dosing makes a missed dose more consequential than it sounds, because one missed week is one missed dose rather than one of seven.

• Catch-up windows are product specific. Approved labelling defines a window in which a missed weekly dose can still be taken, after which the dose is skipped and the normal schedule resumes. Once-weekly tirzepatide labelling allows a missed dose to be taken within 4 days, and the semaglutide products define their own windows which differ between the diabetes and weight-management presentations [1][2]. Read the instructions for use for the exact product in your hand rather than assuming a rule carries across brands.
• Never double up. Taking two doses close together to compensate reproduces the exact scenario the titration ladder exists to avoid.
• Long gaps usually mean re-titration. After several missed weeks, tolerance to the gastrointestinal effects has faded. Restarting at a lower rung and climbing again is the common clinical approach.
• A dose hold is a legitimate tool. Staying at the current dose for an extra cycle, rather than stepping up on schedule, is a normal response to symptoms and is not a failure of the protocol.
• Changing your injection day. Weekly products generally allow the day to be moved provided a minimum interval has passed since the last dose. The label states that interval.

Injection technique is unchanged across the class: subcutaneous into the abdomen, thigh or upper arm, rotating sites so that repeated injection into one spot does not create lipohypertrophy, which absorbs unpredictably and can quietly change the effective dose.

Use this before each scheduled increment. It is the same set of questions a prescriber works through, written so you can arrive at the appointment with the answers.

1. Have I completed the full interval at the current dose? Four weeks for most weekly products, one week for daily liraglutide. Stepping early is the most common self-inflicted tolerability problem.
2. Are the side effects from the last step fully settled? If nausea is still present on the day of the increment, the honest answer is that the current rung is not finished.
3. Is the current dose already delivering the result? If the target is being met, escalation buys risk without a clear return.
4. Do I know the exact measurement for the next dose? For a pen, which device and which dial position. For a vial, the concentration and the number of units. Write it down before the injection, not during it.
5. Has anything changed medically since the last step? New medicines, pregnancy plans, gallbladder or pancreatic symptoms, or a hospital admission all warrant a conversation before climbing further.

If you are weighing two specific compounds rather than two doses, our tirzepatide versus semaglutide comparison sets the two schedules against each other directly, and each compound page carries its own titration table and reconstitution calculator.